Q2 2026 · Form 13F LedgerData source: SEC EDGAR  
H

HOLDER.TOP

Who owns what — the quarterly ledger of U.S. institutional holdings.
EN · 简 · 繁
Funds / KVP Capital Advisors, LP
Form 13F · Q2 2026

KVP Capital Advisors, LP

CIK 1858198Filed 2026-08-1313F-HR View the filing on EDGAR ↗
$136M
Reported book value
35
Positions
3
Quarters on record
Top 50
Positions

KVP Capital Advisors, LP — holdings

Top 35 positions of 35, ranked by reported value. Share change is versus the previous quarter.
#SecuritySharesShare Δ QoQValue% of book
1PRAX Praxis Precision Medicines I42,900+0.0%$14M10.5%
2WHWK Whitehawk Therapeutics Inc2.2M+0.0%$10M7.3%
3ERAS Erasca Inc455,000+33.8%$8M6.1%
4TRVI Trevi Therapeutics Inc414,000+0.0%$8M5.7%
5STRO Sutro Biopharma Inc226,575+0.0%$8M5.5%
6TNGX Tango Therapeutics Inc230,264+0.0%$7M5.3%
7MBX Mbx Biosciences Inc121,524+0.0%$7M4.9%
8PTGX Protagonist Therapeutics Inc53,000+0.0%$6M4.8%
9EWTX Edgewise Therapeutics Inc133,000+0.0%$5M4.0%
10TNDM Tandem Diabetes Care Inc301,000—$5M3.3%
11IRON Disc Medicine Inc58,250+0.0%$4M3.1%
12SVRA Savara Inc605,280+0.0%$4M2.7%
13AVBP Arrivent Biopharma Inc102,000—$4M2.6%
14INSM Insmed Inc28,497+0.0%$3M2.2%
15QUIT Achieve Life Science Inc462,355+0.0%$3M2.2%
16IDYA Ideaya Biosciences Inc79,700+0.0%$3M2.2%
17OCUL Ocular Therapeutix Inc300,000+0.0%$3M2.2%
18AXSM Axsome Therapeutics Inc.12,000−66.9%$3M2.2%
19DSGN Design Therapeutics Inc185,000—$3M2.0%
20UTHR United Therapeutics Corp Del4,750+0.0%$3M1.9%
21SRRK Scholar Rock Hldg Corp45,000+0.0%$2M1.8%
22IMMX Immix Biopharma Inc230,423+0.0%$2M1.7%
23VRDN Viridian Therapeutics Inc125,000+0.0%$2M1.7%
24MLYS Mineralys Therapeutics Inc84,168—$2M1.7%
25DRUG Bright Minds Biosciences Inc31,813+0.0%$2M1.6%
26TVTX Travere Therapeutics Inc39,000−57.1%$2M1.6%
27ZURA Zura Bio Ltd373,128+0.0%$2M1.6%
28ARTV Artiva Biotherapeutics Inc200,000—$2M1.4%
29NKTR Nektar Therapeutics26,900+0.0%$2M1.4%
30CMPX Compass Therapeutics Inc771,000+54.2%$2M1.2%
31CABA Cabaletta Bio Inc505,431+0.0%$2M1.2%
32VERA Vera Therapeutics Inc32,700+0.0%$1M1.0%
33EOLS Evolus Inc150,000—$1M0.8%
34CELC Celcuity Inc4,000+0.0%$418,4800.3%
35VYNE THERAPEUTICS INC Vyne Therapeutics Inc500,551+0.0%$325,7090.2%
Source: Form 13F filings via SEC EDGAR. Positions as of Jun 30, 2026. Options (put/call) are excluded from share counts.